Arrowhead Pharmaceuticals (ARWR) had the highest return in 2018 by a mid-cap US stock, returning 236.6%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Arrowhead Pharmaceuticals (ARWR) | 2018 | 236.59% |
Xenon Pharmaceuticals (XENE) | 2018 | 125.36% |
Glaukos (GKOS) | 2018 | 116.87% |
Energy of Minas Gerais Co DRC (CIG.C) | 2018 | 113.68% |
Krystal Biotech (KRYS) | 2018 | 107.8% |
Acm Research (ACMR) | 2018 | 107.24% |
Crocs (CROX) | 2018 | 105.54% |
CleanSpark (CLSK) | 2018 | 105% |
PTC Therapeutics (PTCT) | 2018 | 103.56% |
Enphase Energy (ENPH) | 2018 | 97.91% |
Veracyte (VCYT) | 2018 | 92.06% |
Viking Therapeutics (VKTX) | 2018 | 87.04% |
Sunrun (RUN) | 2018 | 85.2% |
Wingstop (WING) | 2018 | 84.9% |
Applied Digital (APLD) | 2018 | 83.33% |
Vicor (VICR) | 2018 | 79.52% |
Twist Bioscience (TWST) | 2018 | 77.62% |
HCI (HCI) | 2018 | 75.75% |
Companhia Energetica de Minas Gerais CEMIG Pref ADR (CIG) | 2018 | 75.53% |
Liquidia Technologies (LQDA) | 2018 | 73.98% |
SPS Commerce (SPSC) | 2018 | 69.19% |
Ringcentral (RNG) | 2018 | 68.93% |
Freshpet (FRPT) | 2018 | 68.38% |
First Bancorp (FBP) | 2018 | 68.2% |
Integer (ITGR) | 2018 | 67.24% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
